Singapore markets close in 3 hours 19 minutes
Straits Times Index
3,308.97 +8.97 (+0.27%) Nikkei
38,619.29 -13.73 (-0.04%) Hang Seng
18,051.21 -284.11 (-1.55%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,559.81 -811.82 (-1.24%) CMC Crypto 200
1,351.52 -31.15 (-2.25%)
PCVX Oct 2024 75.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:51PM EDT. Market open.
| Previous close | 20.81 |
| Open | N/A |
| Bid | 13.70 |
| Ask | 18.00 |
| Strike | 75.00 |
| Expiry date | 2024-10-18 |
| Day's range | 20.81 - 20.81 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.